-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network December 1st, November 28th, CDE official website data show that Qilu Pharmaceuticals declared bromomonide lor eye drops 4 imitation listing applications were accepted.
This product is suitable for reducing the open angle glazing and high eye pressure patients in the eye pressure, the current domestic market only the United States Aer Jian approved imports, Qilu Pharmaceuticals for the product's first declared imitation listed pharmaceutical companies.
Figure 1: Chilu Pharmaceuticals Declared Brommonide Lore Eye Drop Source: CDE Official Website Figure 2: Market Size of Ophthalmology Drug Use Source: Minnet China's Public Medical Institutions Terminal Competition Pattern Minnet Data Show that in 2019 in China's urban public hospitals, The market size of end ophthalmology drugs in county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) has exceeded 10 billion, with sales growth exceeding 10% in 2017-2019 and a decline of 8.10% in the first half of 2020 due to the impact of the epidemic.
top 18 companies in the top 20, with a market share of 1.17 percent in the first half of 2020, up 0.07 percent from 2019.
Form 1: Application for the listing of ophthalmology drugs approved by Qilu from 2017 to date Source: Mednet MED2.0 China Drug Review Database Table 2: Qilu's current application for listing of ophthalmology drugs Source: MED2.0 China's drug review database 2017 so far, Qilu has three major ophthalmology generic drugs approved for the market, of which Ratantam eye drops for the domestic first imitation, the product entered the market after the original research Pfizer market share fell to 93.91 percent of 2020H1.
Currently, in addition to the newly declared brominated monitin or lore eye drops, Qilu still has two high-end imitation ophthalmic drugs in the review approval, involving cyclosporine eye drops (II.) and citric acid bromonide eye drops.
: CDE official website, Minet database review data statistics as of November 30, 2020, if there are errors, please point out.
。